Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Room L-134, Stanford, CA 94305-5105, USA.
Department of Quality, Patient Safety and Effectiveness, Stanford Health Care, 300 Pasteur Drive Lane 134, Stanford, CA 94305, USA.
Infect Dis Clin North Am. 2020 Dec;34(4):849-861. doi: 10.1016/j.idc.2020.04.003. Epub 2020 Sep 30.
Vancomycin and daptomycin are options for the initial treatment of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Treatment options for persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains include daptomycin, ceftaroline, and combination therapies. There is a critical need for high-level evidence from clinical trials to allow optimally informed decisions in the treatment of MRSA bacteremia.
万古霉素和达托霉素是治疗耐甲氧西林金黄色葡萄球菌 (MRSA) 菌血症患者的初始选择。对于持续性 MRSA 菌血症或万古霉素中介或耐药株引起的菌血症，治疗选择包括达托霉素、头孢洛林和联合治疗。非常需要来自临床试验的高级别证据，以便在治疗 MRSA 菌血症时做出最佳知情决策。
